Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) have received a consensus recommendation of “Moderate Buy” from the twenty-five analysts that are presently covering the stock, MarketBeat.com reports. Nine analysts have rated the stock with a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $793.8095.

Several equities analysts have weighed in on REGN shares. Wall Street Zen downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday. HSBC raised shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research note on Monday, November 24th. Canaccord Genuity Group upped their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research note on Thursday, December 4th. Evercore increased their target price on Regeneron Pharmaceuticals from $750.00 to $875.00 and gave the company an “outperform” rating in a report on Thursday, January 22nd. Finally, Wells Fargo & Company raised their price target on Regeneron Pharmaceuticals from $745.00 to $800.00 and gave the stock an “equal weight” rating in a research report on Monday, February 2nd.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares in the company, valued at approximately $13,860,169.59. This represents a 0.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The stock was sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at approximately $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 3,636 shares of company stock valued at $2,862,920. 7.02% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. OMERS ADMINISTRATION Corp grew its position in shares of Regeneron Pharmaceuticals by 76.9% in the fourth quarter. OMERS ADMINISTRATION Corp now owns 6,794 shares of the biopharmaceutical company’s stock valued at $5,244,000 after purchasing an additional 2,954 shares during the period. Sienna Gestion boosted its stake in Regeneron Pharmaceuticals by 202.8% in the 4th quarter. Sienna Gestion now owns 1,499 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 1,004 shares during the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA grew its holdings in Regeneron Pharmaceuticals by 6.2% in the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 376 shares of the biopharmaceutical company’s stock valued at $290,000 after buying an additional 22 shares during the period. Tamar Securities LLC increased its stake in shares of Regeneron Pharmaceuticals by 25.4% during the 4th quarter. Tamar Securities LLC now owns 40,456 shares of the biopharmaceutical company’s stock valued at $31,227,000 after acquiring an additional 8,190 shares during the last quarter. Finally, Truvestments Capital LLC increased its stake in shares of Regeneron Pharmaceuticals by 101.9% during the 4th quarter. Truvestments Capital LLC now owns 105 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 53 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 2.5%

REGN opened at $803.17 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.39 and a current ratio of 4.13. The company has a market cap of $84.91 billion, a price-to-earnings ratio of 19.33, a PEG ratio of 2.16 and a beta of 0.40. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $821.11. The business’s fifty day moving average is $764.16 and its two-hundred day moving average is $668.40.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter last year, the business posted $12.07 earnings per share. The business’s revenue for the quarter was up 2.5% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 5th. Investors of record on Friday, February 20th will be given a dividend of $0.94 per share. The ex-dividend date is Friday, February 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 8.47%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.